<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428751</url>
  </required_header>
  <id_info>
    <org_study_id>308-2015-005</org_study_id>
    <nct_id>NCT02428751</nct_id>
  </id_info>
  <brief_title>R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma</brief_title>
  <official_title>Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wenqi Jiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
      (R-CHOP regimen) has been the first-line chemotherapy for elderly patients with diffuse large
      B-cell lymphoma (DLBCL). The treatment-related toxicities, especially the severe cardiac
      toxicities induced by anthracycline drugs (doxorubicin), have become a major concern among
      elderly patients. Pegylated liposomal doxorubicin is a formulation of doxorubicin with a
      prolonged circulation time and unique toxicity profile. Previous single arm studies of
      elderly patients with lymphoma used pegylated liposomal doxorubicin instead of traditional
      doxorubicin in combination with rituximab, cyclophosphamide, vincristine, and prednisone (the
      novel R-CDOP regimen), and demonstrated better safety profile, including less bone marrow
      suppression and less cardiac toxicities, while maintaining the efficacy. However, the
      efficacy and safety of these two regimens (R-CHOP and R-CDOP) have not been head-to-head
      compared in a randomized study. The aim of this study is to compare the efficacy and safety
      of R-CDOP (rituximab, cyclophosphamide, pegylated liposomal doxorubicin, vincristine, and
      prednisone) and R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and
      prednisone) in previously untreated elderly patients with DLBCL.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event-free survival (EFS)</measure>
    <time_frame>two year</time_frame>
    <description>Defined as time from the date of randomization to the date of disease progression, death due to any cause, termination of treatment, or the most recent follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate (ORR)</measure>
    <time_frame>at week 6, 12, 18, and 24 after randomization</time_frame>
    <description>defined as the proportion of patients whose best overall response is either complete remission (CR) or partial remission (PR), which was evaluated in accordance with the International Working Group Recommendations for Response Criteria for non-Hodgkin's lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete remission (CR) rate</measure>
    <time_frame>at week 6, 12, 18, and 24 after randomization</time_frame>
    <description>defined as the proportion of patients whose best overall response is complete remission, which was evaluated in accordance with the International Working Group Recommendations for Response Criteria for non-Hodgkin's lymphoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>two year</time_frame>
    <description>defined as time from the date of randomization to the date of death due to any cause or the most recent follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group received R-CHOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Doxorubicin, 50mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CDOP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group received R-CDOP regimen as the first-line chemotherapy. Rituximab, 375mg/m2, iv, d0; Cyclophophamide, 750mg/m2, iv, d1; Pegylated liposomal doxorubicin, 30mg/m2, iv, d1; Vincristine, 2mg/m2 (max 2mg), iv, d1; Prednisone, 100mg, po, d1-5. Repeat every 21 days for 6-8 cycles or until the criteria of terminating treatment was met.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle</description>
    <arm_group_label>R-CDOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-CDOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophophamide</intervention_name>
    <description>750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-CDOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-CDOP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>100mg/d, PO on day 1-5 of each 21 day cycle</description>
    <arm_group_label>R-CHOP</arm_group_label>
    <arm_group_label>R-CDOP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed diagnosis of CD20-positive diffuse large B-cell lymphoma

          -  60~80 years old

          -  Ann Arbor stage I~IV

          -  ECOG physical score of 0~2

          -  Have not received previous treatment to lymphoma, including chemotherapy,
             radiotherapy, or biotherapy

          -  Have at least one clinically measurable lesion: &gt;= 2cm under physical examination, or
             &gt;= 1.5cm under computed tomography (CT) or magnetic resonance (MR)

          -  Life expectancy of &gt;= 3 months

          -  Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate
             transaminase and total bilirubin &lt;= 2 × upper limit of normal (ULN)

          -  Glomerular filtration rate (MDRD method) &gt;= 30ml/min

          -  No abnormalities in blood coagulative function

          -  Generally normal bone marrow function: while blood cell &gt;= 3,000/μL, absolute
             neutrophil count &gt;= 1,500/μL, hemoglobin &gt;= 100g/L, platelet &gt;= 75,000/μL

          -  No evidence of active hepatitis B or C virus, or human immunodeficiency virus
             infection

          -  Left ventricular ejection fraction (LVEF) &gt;= 45% measured by two dimensional
             echocardiography or multi-gated acquisition (MUGA) scan

          -  Cardiac function of class I-II in New York Heart Association (NYHA) classification

        Exclusion Criteria:

          -  Patients with indolent lymphoma

          -  Positive results for in situ hybridization for Epstein-Barr virus encoded RNA (EBER)

          -  Serum Epstein-Barr virus DNA &gt;= 1,000 copies/ml

          -  Double-hit lymphoma confirmed by fluorescence in situ hybridization (FISH)

          -  Primary mediastinal B-cell lymphoma

          -  Involvement of central nervous system

          -  Bulky disease (&gt;= 10cm)

          -  History of cardiac disease, including clinically significant ventricular tachycardia,
             atrial fibrillation, conduction block, myocardial infarction within 1 year, congestive
             heart failure, symptomatic coronary heart disease which needs medication

          -  Known allergic reaction to any component of the agents used in the chemotherapeutic
             regimens that are used in the study

          -  Previous exposure to anthracycline drugs, rituximab, or chemotherapy for lymphoma

          -  History of malignant carcinoma within 5 years (except carcinoma in situ of the skin
             and uterine cervix, and prostatic carcinoma)

          -  Currently enrolled in other clinical studies

          -  Other conditions that the investigators consider as inappropriate for enrolling into
             this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-qi Jiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wen-qi Jiang, M.D.</last_name>
    <phone>86-20-87343765</phone>
    <email>wenqi_jiang@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xi-wen Bi, M.D.</last_name>
    <phone>86-13826050380</phone>
    <email>xiwen_bi@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen-yu Li, M.D.</last_name>
      <phone>86-13924196915</phone>
    </contact>
    <investigator>
      <last_name>Wen-yu Li, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xin Du, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital of Southern Medical Unversity</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bing Xu, M.D.</last_name>
      <phone>86-18688900980</phone>
    </contact>
    <investigator>
      <last_name>Bing Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi-ming Li, M.D.</last_name>
      <phone>86-13719189172</phone>
      <email>zhimingsysucc@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xi-wen Bi, M.D.</last_name>
      <phone>86-13826050380</phone>
      <email>xiwen_bi@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wen-qi Jiang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huo Tan, M.D.</last_name>
      <phone>86-13602725539</phone>
    </contact>
    <investigator>
      <last_name>Huo Tan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li-ping Ma, M.D.</last_name>
      <phone>86-13600450776</phone>
    </contact>
    <investigator>
      <last_name>Li-ping Ma, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiang-yuan Wu, M.D.</last_name>
      <phone>86-13729813256</phone>
    </contact>
    <investigator>
      <last_name>Xiang-yuan Wu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wujing Zongdui Hospital of Guangdong Province</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Zhou, M.D.</last_name>
      <phone>86-18820019866</phone>
    </contact>
    <investigator>
      <last_name>Tao Zhou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002-6.</citation>
    <PMID>7680764</PMID>
  </results_reference>
  <results_reference>
    <citation>Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005 Jun 20;23(18):4117-26. Epub 2005 May 2.</citation>
    <PMID>15867204</PMID>
  </results_reference>
  <results_reference>
    <citation>Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 Sep 23;116(12):2040-5. doi: 10.1182/blood-2010-03-276246. Epub 2010 Jun 14.</citation>
    <PMID>20548096</PMID>
  </results_reference>
  <results_reference>
    <citation>Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 Jan 24;346(4):235-42.</citation>
    <PMID>11807147</PMID>
  </results_reference>
  <results_reference>
    <citation>Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, Dakhil SR, Woda B, Fisher RI, Peterson BA, Horning SJ. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006 Jul 1;24(19):3121-7. Epub 2006 Jun 5.</citation>
    <PMID>16754935</PMID>
  </results_reference>
  <results_reference>
    <citation>Limat S, Daguindau E, Cahn JY, Nerich V, Brion A, Perrin S, Woronoff-Lemsi MC, Deconinck E. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma. J Clin Pharm Ther. 2014 Apr;39(2):168-74. doi: 10.1111/jcpt.12124. Epub 2014 Jan 3.</citation>
    <PMID>24384030</PMID>
  </results_reference>
  <results_reference>
    <citation>Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P, Markopoulos C. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2002 Nov;13(11):1737-42.</citation>
    <PMID>12419745</PMID>
  </results_reference>
  <results_reference>
    <citation>Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, Dharmapala D, Gee C, Boswell WD, Nathwani BN, Welles L, Levine AM. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma. Clin Lymphoma Myeloma. 2006 Jul;7(1):59-64.</citation>
    <PMID>16879771</PMID>
  </results_reference>
  <results_reference>
    <citation>O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler C; CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004 Mar;15(3):440-9.</citation>
    <PMID>14998846</PMID>
  </results_reference>
  <results_reference>
    <citation>Luminari S, Montanini A, Caballero D, Bologna S, Notter M, Dyer MJ, Chiappella A, Briones J, Petrini M, Barbato A, Kayitalire L, Federico M. Nonpegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial. Ann Oncol. 2010 Jul;21(7):1492-9. doi: 10.1093/annonc/mdp544. Epub 2009 Dec 11.</citation>
    <PMID>20007997</PMID>
  </results_reference>
  <results_reference>
    <citation>Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, Amore A, Capobianco G, Caronna A, Becchimanzi C, Volzone F, Marcacci G, Russo F, De Filippi R, Mastrullo L, Pinto A. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. Br J Haematol. 2011 Sep;154(5):579-89. doi: 10.1111/j.1365-2141.2011.08786.x. Epub 2011 Jun 28.</citation>
    <PMID>21707585</PMID>
  </results_reference>
  <results_reference>
    <citation>Zaja F, Tomadini V, Zaccaria A, Lenoci M, Battista M, Molinari AL, Fabbri A, Battista R, Cabras MG, Gallamini A, Fanin R. CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2006 Oct;47(10):2174-80.</citation>
    <PMID>17071492</PMID>
  </results_reference>
  <results_reference>
    <citation>Rigacci L, Mappa S, Nassi L, Alterini R, Carrai V, Bernardi F, Bosi A. Liposome-encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre-treated with anthracyclines. Hematol Oncol. 2007 Dec;25(4):198-203.</citation>
    <PMID>17654614</PMID>
  </results_reference>
  <results_reference>
    <citation>Visani G, Guiducci B, D'Adamo F, Mele A, Nicolini G, Leopardi G, Sparaventi G, Barulli S, Malerba L, Isidori A, Malagola M, Piccaluga PP. Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 Mar;46(3):477-9.</citation>
    <PMID>15621843</PMID>
  </results_reference>
  <results_reference>
    <citation>Heintel D, Skrabs C, Hauswirth A, Eigenberger K, Einberger C, Raderer M, Sperr WR, Knöbl P, Müllauer L, Uffmann M, Dieckmann K, Gaiger A, Jäger U. Nonpegylated liposomal doxorubicin is highly active in patients with B and T/NK cell lymphomas with cardiac comorbidity or higher age. Ann Hematol. 2010 Feb;89(2):163-9. doi: 10.1007/s00277-009-0796-5. Epub 2009 Jul 28.</citation>
    <PMID>19636553</PMID>
  </results_reference>
  <results_reference>
    <citation>Gimeno E, Sánchez-González B, Alvarez-Larrán A, Pedro C, Abella E, Comín J, Saumell S, García-Pallarols F, Gómez M, Besses C, Salar A. Intermediate dose of nonpegylated liposomal doxorubicin combination (R-CMyOP) as first line chemotherapy for frail elderly patients with aggressive lymphoma. Leuk Res. 2011 Mar;35(3):358-62. doi: 10.1016/j.leukres.2010.07.024. Epub 2010 Aug 12.</citation>
    <PMID>20708263</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Wenqi Jiang</investigator_full_name>
    <investigator_title>Chief of Department of Internal Medicine, Sun Yat-sen University Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Lymphoma, Large B-Cell, Diffuse</keyword>
  <keyword>liposomal doxorubicin</keyword>
  <keyword>doxorubicin</keyword>
  <keyword>event-free survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

